WooGene B&G Co. Ltd - Asset Resilience Ratio
WooGene B&G Co. Ltd (018620) has an Asset Resilience Ratio of 3.35% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is WooGene B&G Co. Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how WooGene B&G Co. Ltd's Asset Resilience Ratio has changed over time. See WooGene B&G Co. Ltd (018620) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down WooGene B&G Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is WooGene B&G Co. Ltd worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩3.92 Billion | 3.35% |
| Total Liquid Assets | ₩3.92 Billion | 3.35% |
Asset Resilience Insights
- Limited Liquidity: WooGene B&G Co. Ltd maintains only 3.35% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
WooGene B&G Co. Ltd Industry Peers by Asset Resilience Ratio
Compare WooGene B&G Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 4.82% |
|
ST Pharm Co.Ltd
KQ:237690 |
Pharmaceuticals | 7.72% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 65.38% |
|
Caregen Co.Ltd
KQ:214370 |
Pharmaceuticals | 4.58% |
|
Kolon Life Science Inc
KQ:102940 |
Pharmaceuticals | 1.22% |
|
Mezzion Pharma Co.Ltd
KQ:140410 |
Pharmaceuticals | 13.09% |
|
Komipharm International Co. Ltd
KQ:041960 |
Pharmaceuticals | 0.00% |
Annual Asset Resilience Ratio for WooGene B&G Co. Ltd (2011–2024)
The table below shows the annual Asset Resilience Ratio data for WooGene B&G Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 18.41% | ₩20.78 Billion ≈ $14.08 Million |
₩112.87 Billion ≈ $76.49 Million |
+3.62pp |
| 2023-12-31 | 14.79% | ₩17.98 Billion ≈ $12.18 Million |
₩121.58 Billion ≈ $82.39 Million |
-12.17pp |
| 2022-12-31 | 26.96% | ₩24.67 Billion ≈ $16.72 Million |
₩91.52 Billion ≈ $62.02 Million |
+6.31pp |
| 2021-12-31 | 20.65% | ₩15.80 Billion ≈ $10.71 Million |
₩76.51 Billion ≈ $51.85 Million |
+4.23pp |
| 2020-12-31 | 16.42% | ₩12.74 Billion ≈ $8.63 Million |
₩77.56 Billion ≈ $52.56 Million |
+9.43pp |
| 2019-12-31 | 6.99% | ₩5.95 Billion ≈ $4.03 Million |
₩85.13 Billion ≈ $57.69 Million |
+2.52pp |
| 2018-12-31 | 4.47% | ₩2.69 Billion ≈ $1.82 Million |
₩60.05 Billion ≈ $40.69 Million |
+3.78pp |
| 2017-12-31 | 0.69% | ₩420.69 Million ≈ $285.09K |
₩60.64 Billion ≈ $41.09 Million |
-9.76pp |
| 2016-12-31 | 10.45% | ₩6.08 Billion ≈ $4.12 Million |
₩58.15 Billion ≈ $39.40 Million |
+7.98pp |
| 2015-12-31 | 2.47% | ₩1.04 Billion ≈ $706.40K |
₩42.24 Billion ≈ $28.63 Million |
+2.19pp |
| 2014-12-31 | 0.28% | ₩81.83 Million ≈ $55.46K |
₩29.06 Billion ≈ $19.70 Million |
-3.00pp |
| 2012-12-31 | 3.28% | ₩858.38 Million ≈ $581.71K |
₩26.18 Billion ≈ $17.74 Million |
+2.44pp |
| 2011-12-31 | 0.84% | ₩216.00 Million ≈ $146.38K |
₩25.81 Billion ≈ $17.49 Million |
-- |
About WooGene B&G Co. Ltd
WooGene B&G Co., Ltd. develops, manufactures, and markets products to animal health and livestock industry in South Korea and internationally. The company's products include veterinary medicines, raw materials, and probiotic. It offers veterinary medicines for poultry, swine, bovine, horse, dog, cat, sheep, deer, and aquaculture markets; and vaccines for swine, poultry, canine, and cow markets. T… Read more